Checkpoint Therapeutics announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma during the European Society for Medical Oncology, ESMO, Congress 2024, which is taking place in Barcelona, Spain, from September 13 to 17, 2024. With 16 months of additional follow-up since the primary analysis, cosibelimab demonstrated increasing objective response rates and complete response rates per independent central review in 109 patients with advanced cSCC. Overall, in 192 advanced cSCC patients treated with cosibelimab, a manageable safety profile was observed, with notable low rates of treatment-emergent adverse events, severe immune-related adverse events, and treatment discontinuations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CKPT:
- Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
- Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Checkpoint Therapeutics files to sell 6.2M shares of common stock for holders
- Checkpoint Therapeutics price target lowered to $20 from $34 at H.C. Wainwright
- Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates